Survey of Ophthalmology
Volume 54, Issue 6 , Pages 705-707 , November 2009

Position Paper: The Need for Head-to-Head Studies Comparing Avastin versus Lucentis

  • Christine Schmucker, PhD

      Affiliations

    • German Cochrane Center, University Medical Center Freiburg, Germany
    • Corresponding Author InformationReprint address: Christine Schmucker, PhD, German Cochrane Center, Institute of Medical Biometry and Medical Informatics, Department of Medical Biometry and Statistics, University Medical Center Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany.
    • ,
  • Gerd Antes, PhD

      Affiliations

    • German Cochrane Center, University Medical Center Freiburg, Germany
    • ,
  • Monika Lelgemann, MD, MSc

      Affiliations

    • Health Technology Assessment Center, University Bremen, Germany

References 

  1. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249–256
  2. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125:1357–1361
  3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  4. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957–1959
  5. Falkenstein IA, Cheng L, Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina. 2007;27:701–706
  6. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–1349
  7. Geitzenauer W, Michels S, Prager F, et al. Early effects of systemic and intravitreal bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd. 2006;223:822–827
  8. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degenereation. Ophthalmologe. 2007;104:588–593
  9. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68–73
  10. Lazic R, Gabric N, Dekaris I, et al. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol. 2007;31(Suppl 1):S315–S319
  11. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179–1185
  12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  13. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-terms results. Eye. 2009;1–5
  14. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–1412
  15. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol. 2008;92:356–360
  16. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–87

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. The work was supported by a grant of the German health insurance companies.

PII: S0039-6257(09)00207-0

doi: 10.1016/j.survophthal.2009.08.002

Survey of Ophthalmology
Volume 54, Issue 6 , Pages 705-707 , November 2009

Article Tools